Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
3/23/2026, 12:00:00 AM
Presentation of positive Phase 3 results for Camzyos (mavacamten) in treating adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) on March 23, 2026; 1% price impact estimated from clinical data, scheduled.
Korean Translation
2026년 3월 23일, 청소년의 증상성 폐쇄성 비대성 심근병증(oHCM) 치료에 대한 캠지오스(마바캄텐)의 3상 임상 결과 발표가 예정되어 있으며, 데이터 중요도에 따른 1% 이상의 주가 영향이 예상됨.
Related Recent Events
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release on June 4, 2026; a Medium impact is estimated as quarterly earnings are key drivers of stock volatility, scheduled.
6/4/2026, 12:00:00 AM
CME Group Inc (CME) · Other
CME Group will expand regulated cryptocurrency futures and options trading to 24/7 starting on 2026-05-29, pending regulatory review, scheduled.
5/29/2026, 12:00:00 AM
Dell Technologies Inc (DELL) · Earnings Release
Dell Technologies is scheduled to report its fiscal Q1 2027 earnings on May 28, 2026. Since earnings reports typically drive price movements exceeding 5%, significant volatility is scheduled.
5/28/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA PDUFA action date for the subcutaneous formulation of LEQEMBI for treatment initiation in early Alzheimer's disease is scheduled. This regulatory milestone is estimated to have a medium impact on stock price.
5/24/2026, 12:00:00 AM
ONEOK Inc (OKE) · Other
ONEOK 2026 annual meeting of shareholders on May 20, 2026, is estimated to have a price impact of at least 1% and is scheduled.
5/20/2026, 12:00:00 AM
Keysight Technologies Inc (KEYS) · Earnings Release
Keysight Technologies' fiscal second-quarter 2026 earnings report is scheduled for May 19, 2026; a price movement of 5% or more is expected.
5/19/2026, 12:00:00 AM